Canada has a new way to turn the country’s $6-billion investment in basic health research into successful and well-managed companies. Accel-Rx will partner with BDC Capital to invest up to $1,000,000—matched by other investors—in three to four life sciences companies annually. Five health‑related CECRs representing 70% of the country’s drug development pipeline will share their most commercially promising discoveries with Accel-Rx. The new CECR will make them investment-ready by providing entrepreneurial training and access to capital, specialized infrastructure, strategic partners and experienced entrepreneurs.